News
MyChesCo on MSN1mon
Virpax Pharmaceuticals to Present NES100 Toxicity Study at Major Toxicology ConferenceBERWYN, PA — Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) has announced that findings from its dose range toxicity study for NES100, an innovative intranasal peptide for managing acute and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback